Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (HDP1:DUS) closed at 55.22, -13.37% below its 52-week high of 63.74, set on Jan 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 54.30 |
|---|---|
| High | 55.22 |
| Low | 54.04 |
| Bid | 54.38 |
| Offer | 54.68 |
| Previous close | 57.74 |
| Average volume | 20.00 |
|---|---|
| Shares outstanding | 140.01m |
| Free float | 134.68m |
| P/E (TTM) | -- |
| Market cap | 9.05bn USD |
| EPS (TTM) | -0.0644 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 15:00 GMT.
More ▼
Press releases
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
- Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
- Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
- Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
- Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
More ▼
